Oral extended-release oxymorphone: A new choice for chronic pain relief

Research output: Contribution to journalArticle

Abstract

Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.

Original languageEnglish (US)
Pages (from-to)1515-1527
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number10
DOIs
StatePublished - Jul 2007

Fingerprint

Oxymorphone
Chronic Pain
Opioid Analgesics
Opioid Receptors
Osteoarthritis
Half-Life
Safety
Therapeutics

Keywords

  • Analgesia
  • Chronic pain
  • Opioids
  • Oxymorphone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Oral extended-release oxymorphone : A new choice for chronic pain relief. / Matsumoto, Alan K.

In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 10, 07.2007, p. 1515-1527.

Research output: Contribution to journalArticle

@article{1afcf6b7a0684c078578ef38475c8598,
title = "Oral extended-release oxymorphone: A new choice for chronic pain relief",
abstract = "Opana{\circledR} ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.",
keywords = "Analgesia, Chronic pain, Opioids, Oxymorphone",
author = "Matsumoto, {Alan K.}",
year = "2007",
month = "7",
doi = "10.1517/14656566.8.10.1515",
language = "English (US)",
volume = "8",
pages = "1515--1527",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Oral extended-release oxymorphone

T2 - A new choice for chronic pain relief

AU - Matsumoto, Alan K.

PY - 2007/7

Y1 - 2007/7

N2 - Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.

AB - Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.

KW - Analgesia

KW - Chronic pain

KW - Opioids

KW - Oxymorphone

UR - http://www.scopus.com/inward/record.url?scp=34447521417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447521417&partnerID=8YFLogxK

U2 - 10.1517/14656566.8.10.1515

DO - 10.1517/14656566.8.10.1515

M3 - Article

C2 - 17661733

AN - SCOPUS:34447521417

VL - 8

SP - 1515

EP - 1527

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -